Clinical Trial Update: Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated a triplet regimen of bortezomib, liposomal doxorubicin, and thalidomide as first-line therapy for patients with untreated stage I–I…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Plasma Cell Neoplasm

Drugs mentioned

• Bortezomib (bortezomib)
• DOXORUBICIN HYDROCHLORIDE LIPOSOME (DOXORUBICIN HYDROCHLORIDE)
• Thalidomide (thalidomide)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Multiple Myeloma and Plasma Cell Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2013-09-17